CD274 and neoplasm: Liu et al. developed a dual-responsive engineered nanoparticle, CMFn@OXA, based on ferritin for enhanced tumor-targeted delivery and controlled release of an anti-PD-L1 peptide (CLP002) and the chemotherapeutic drug oxaliplatin (OXA).